BioSpace News Archive

The Tack® implant is a first-of-its kind device for patients with peripheral arterial disease and/or critical limb ischemia

Advanced Energy Sales of approximately $4.4 to $4.5 million in Q4, up 43% to 47% year-over-year

The FDA’s Fast Track designation is a process to facilitate development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

Company achieved its latest full-year 2018 guidance; will report Q4 2018 results on January 31, 2019

For fiscal 2018, total preliminary, unaudited revenue is expected to exceed $1.025 billion, an increase of more than 42% over 2017.

Arrowhead intends to proceed with AROAPOC31001, a Phase 1 single and multiple dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of ARO-APOC3 in adult healthy volunteers, hypertriglyceridemic patients, and patients with familial chylomicronemia syndrome

Leading healthcare company continues to build on its transformational model for achieving value-based care success.

Regulus Therapeutics, Inc. announced the nomination of RGLS5579 as a clinical candidate for the treatment of glioblastoma multiforme (“GBM”)

Stelexis is a Deerfield founded and solely funded company

Apple Tree Partners has announced the following promotions: Sam Hall, Ph.D., to Partner, Aaron Kantoff to Partner, Christine Borowski, Ph.D., to Principal, and Jernej Godec, Ph.D., to Senior Associate, who joins Chris Cain, Ph.D., also a Senior Associate.